Nirmatrelvir is the first 3CLpro inhibitor authorized for treatment of COVID-19 patients at high risk of hospitalization. We recently reported on the in vitro selection of SARS-CoV-2 3CLpro resistant virus (L50F-E166A-L167F; 3CLprores) that is cross-resistant with nirmatrelvir and ...
Susceptible members of the households with one or more infected cases are considered to quarantine themselves. We also assumed a level of compliance for quarantine (see Table A10). We used hospitalization and death data reported for Miami-Dade County [20] for each age group to obtain ...